Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06334731
Status:
RECRUITING
Last Update Posted:
2024-03-28
First Post:
2022-10-21
Brief Title:
Antimicrobial Resistance During the SARS-CoV-2 COVID-19 Pandemic
Sponsor:
Methodist Health System
Organization:
Methodist Health System
Study Overview
Official Title:
What Happened Antimicrobial Resistance During the SARS-CoV-2 COVID-19 Pandemic
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic
Detailed Description:
The COVID-19 pandemic acceleratedexacerbated resistance rates for key pathogens Specifically incidence of extended-spectrum beta-lactamase producing Enterobacteriaceae ESBLPE carbapenem-resistant bacteria CRB methicillin-resistant Staphyloccoccus aureus MRSA vancomycin-resistant Enterococci VRE and C difficile infections CDI will be higher in the pandemic time period Pandemic March 2020 - February 2025 compared to the pre-pandemic period Pre-Pandemic March 2018 - February 2020
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None